enGene Holdings announced the appointment of Ryan Daws as CFO and Head of Business Development. Daws joins enGene with nearly 25 years of life sciences-focused operational and deal-making experience. Prior to joining enGene, Daws was CFO and Head of Business Development at Obsidian Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENGN: